アスタキサンチンは,血小板活性化と血液凝固の両方を抑制することによって,血栓形成を抑制します
Lili Zhang1,2, Yadan Luo1, Ningwan Lei1
1Department of Pharmacology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, China.
British journal of pharmacology
|February 17, 2026
まとめ
アスタキサンチン (ASX) は,血小板活性化と血液凝固を抑制することによって,血栓形成を効果的に予防します. この抗酸化カロテノイドは,過剰な出血なしに心臓血管の健康と血栓の予防のための新しい戦略を提供します.
科学分野:
- 心血管科学の研究について
- 薬理学 薬理学とは
- バイオケミストリー バイオケミストリー
背景:
- 血栓症は,血小板の活性化と凝固に起因する世界的な主要な死亡原因です.
- カロテノイドであるアスタキサンチン (ASX) は,心臓血管の健康に有益な抗酸化特性を持っています.
研究 の 目的:
- アスタキサンチン (ASX) の抗血栓性可能性を体系的に調査する.
- ASXの抗血栓効果の基礎となる分子メカニズムを解明する.
主な方法:
- ネズミやマウスの体内の研究,ヒトの血小板や肝臓細胞の体内の研究.
- ASXの標的を特定するために,ネットワークの薬理学と免疫ブロッティング.
- トロンブスの成分を視覚化するための腸内顕微鏡検査.
主要な成果:
- ASXは,ROSとダウンストリームシグナリングを阻害することによって,血小板の集積,粘着,拡散,および凝固の収縮を弱めた.
- ASXは,肝臓のROSとHNF4αを減少させることで,内在的および外在的な血液凝固を抑制しました.
- ASXは,動脈と静脈の血栓の予防においてアスピリンと同等の有効性を示したが,過剰な出血を引き起こすことなく,血小板と線維素の両方を抑制した.
結論:
- アスタキサンチン (ASX) は,血小板および肝臓のROSおよび関連する経路を抑制することにより,多面的な抗血栓効果を発揮します.
- ASXは,血栓形成の予防のための有望な新しい治療戦略を提示しています.
関連する概念動画
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
01:22Formation of the Platelet Plug
9.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
9.8K
01:24Disorders of Hemostasis
2.3K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.3K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
13.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
13.5K